Jeffery L. Kutok
Keine laufenden Positionen mehr
Karriereverlauf von Jeffery L. Kutok
Ehemalige bekannte Positionen von Jeffery L. Kutok
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| EPIZYME, INC. | Technik-/Wissenschafts-/F&E-Leiter | 23.03.2020 | 01.09.2022 |
| INFINITY PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2010 | 31.03.2020 |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01.01.2002 | 01.12.2010 |
| Harvard Medical School | Corporate Officer/Principal | 01.01.2002 | 01.12.2010 |
Ausbildung von Jeffery L. Kutok
| Stony Brook University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
The Brigham & Women's Hospital, Inc.
The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Jeffery L. Kutok
- Erfahrung
